Dartmouth College Sample Clauses

Dartmouth College. (DARTMOUTH) seeks to develop an effort to bring its intellectual property and technologies to the marketplace. The goal is to generate on-going royalties or other license revenue for DARTMOUTH to enhance it research capabilities, reward faculty members whose patents are licensed, and to develop new opportunities for sponsored research activities.
AutoNDA by SimpleDocs
Dartmouth College. By: /s/ Xxxx Xxx Xxxx Xxx, Director Technology Transfer Office Date: March 7, 2008 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. APPENDIX G MASTER NONDISCLOSURE AGREEMENT PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. DOE BioEnergy Science Center MASTER NONDISCLOSURE AGREEMENT (NDA) The effective date of this Agreement shall be August 8, 2007 (“Effective Date”). In order to protect certain INFORMATION (defined hereinbelow), UT-BATTELLE, LLC (UT-Battelle), a laboratory contractor (“Lab Contractor”), under the authority of its Prime Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy (DOE) and having an office for business at 0 Xxxxxx Xxxxxx Xxxx, Xxx Xxxxx, Xxxxxxxxx 00000; The University of Tennessee, a university having an office for business at 0000 Xxxxx Xxxxxx, Xxxxxxxxx, XX 00000-0000, (hereinafter referred to as “UT”); University of Tennessee Research Foundation, a non-profit Tennessee corporation having an office for business at 0000 Xxxxx Xxxxxx Xxxxx 000, Xxxxxxxxx, XX 00000-0000, (hereinafter referred to as “UTRF”); Midwest Research Institute, a Lab Contractor, under the authority of its Contract No. DE-AC36-99GO 10337 with DOE and having an office for business at 0000 Xxxx Xxxx, Golden Colorado 80401, (hereinafter referred to as “MRI”); The University of Georgia, having an office for business at 000 Xxxx XXXX, Athens, GA 30602-7411, (hereinafter referred to as “UGA”); The University of Georgia Research Foundation, having an office for business at Xxxx 634, Athens , GA 30602 (hereinafter referred to as “UGARF”) Georgia Tech Research Corporation, a Georgia nonprofit corporation having an office for business at 000 Xxxxx Xxxxxx, Xxxxxxx, Xxxxxxx 00000 (hereinafter referred to as “GTRC”); The Xxxxxx Xxxxxxx Noble Foundation, a nonprofit corporation having an office for business at 0000 Xxx Xxxxx Parkway, Ardmore, Oklahoma 73401, (hereinafter referred to as “Noble”); Trustees of Dartmouth College, having an office for business at 00 Xxxx Xxxxx Xxxx, #0000, Xxxxxxx, XX 00000-0000, (hereinafter referred to as “Dartmouth”); Mascoma Corporation, having an office for business at 000 Xxxxx Xxxxxx...
Dartmouth College. This Agreement, effective this day of 2008, between TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth, and ABC CORPORATION, a corporation of the State of , with a principal place of business at _ , hereinafter called ABC.
Dartmouth College. 1.1.7. The Inter-University Centre for Astronomy and Astrophysics; and
Dartmouth College. Emory University Georgetown University

Related to Dartmouth College

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • citizens abroad 2. Unless the circumstances described in the parenthetical in paragraph 1 above are applicable, either (a) at the time the buy order was originated, the buyer was outside the United States or we and any person acting on our behalf reasonably believed that the buyer was outside the United States or (b) the transaction was executed in, on or through the facilities of a designated offshore securities market, and neither we nor any person acting on our behalf knows that the transaction was pre-arranged with a buyer in the United States.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.